Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of T2DM for at least 12 weeks prior to the Screening Visit~* Currently treated with a stable oral dose of metformin monotherapy for at least 12 weeks prior to the Screening Visit and until Day -3~* Have a glycosylated hemoglobin (HbA1c) value of between 6.5% and 10.0% at the Screening Visit~* Have a fasting plasma glucose (FPG) value of no more than 280 mg/dL at the Screening Visit and on Day -3~* Body Mass Index (BMI) of 25 to 40 kg/m2 (inclusive)~Exclusion Criteria:~* Known medical history or presence of Type 1 diabetes mellitus, Maturity Onset Diabetes of the Young or secondary forms of diabetes~* Known medical history or presence of diabetic complications~* Have taken anti-diabetic medications (other than metformin) or medications that act mainly in the gastrointestinal tract (e.g., orlistat, acarbose) within 12 weeks prior to the Screening Visit or from the Screening Visit to Day -3~* Have uncontrolled hypertension (systolic blood pressure of at least 160 mmHg or diastolic blood pressure of at least 95 mmHg) at the Screening Visit~* Have impaired renal function (estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- JTT-662 5 mg (Type: EXPERIMENTAL): JTT-662 5 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
- JTT-662 10 mg (Type: EXPERIMENTAL): JTT-662 10 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
- JTT-662 20 mg (Type: EXPERIMENTAL): JTT-662 20 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
- Placebo (Type: PLACEBO_COMPARATOR): Placebo orally once daily from Day -1 to Day 28

Based on this trial design, predict the completion outcome and termination type (if applicable).